TECH · 10-Q/A · 2026Q3 · Full report
Operating Expense Trends
BIO-TECHNE Corp · 2026-11-12 · Importance 54 · Surprise 40 · No source text
Selling, general and administrative expense increased 15.0% year over year to $133.7 million from $116.2 million. Research and development expense increased 8.7% to $26.3 million from $24.2 million, while total operating expenses increased 13.9% to $160.0 million. Stock-based compensation expense, inclusive of payroll taxes, rose to $14.0 million from $11.7 million and was included primarily in SG&A.
Key facts
- Selling, general and administrative expenses increased 15% to $133.7 million in the quarter ended September 30, 2026 year over year. source
- Research and development expenses increased 9% to $26.3 million in the quarter ended September 30, 2026 year over year. source
- BIO-TECHNE had $66.8 million of unrecognized share-based compensation cost as of September 30, 2026, expected to be recognized over a weighted average period of 1.7 years. source
- BIO-TECHNE reported total operating lease expense of $5.636 million for the quarter ended September 30, 2026, compared with $5.735 million for the quarter ended September 30, 2025. source
- BIO-TECHNE reported that litigation charges were immaterial during the quarters ended September 30, 2026 and 2025. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | -5.8% | Selling, general and administrative expenses increased 15% to $133.7 million in the quarter ended September 30, 2026 year over year. |
| operating_income | negative | realized | -0.7% | Research and development expenses increased 9% to $26.3 million in the quarter ended September 30, 2026 year over year. |